Literature DB >> 15542202

A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity.

Steven C Derrick1, Amy Li Yang, Sheldon L Morris.   

Abstract

In this study, we evaluated the protective efficacy of a DNA vaccine (pE6/85) expressing an ESAT6-Ag85B fusion protein against a primary Mycobacterium tuberculosis infection in mice. In short-term studies, vaccination with pE6/85 protected as well as Mycobacterium bovis BCG immunization with similar lung pathology and bacterial burdens detected 28 days after a low dose aerogenic challenge (>1.0 log(10) reduction relative to naïves). In a survival experiment, the protection induced by pE6/85 immunization was also not significantly different than that elicited by BCG vaccination with the mean-times-to-death (+/-standard error of the mean) being 102+/-20, 271+/-32 and 299+/-14 days for naïve, pE6/85 and BCG-vaccinated mice, respectively. Furthermore, boosting with pE6/85 but not BCG or a DNA vaccine cocktail at 1 year after an initial BCG immunization (when BCG-induced protection was declining), augmented protection in the lung at 15 and 18 months to levels detected at 3 months post-BCG vaccination.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542202     DOI: 10.1016/j.vaccine.2004.07.036

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  31 in total

1.  Time to detection of Mycobacterium tuberculosis using the MGIT 320 system correlates with colony counting in preclinical testing of new vaccines.

Authors:  K Kolibab; A Yang; M Parra; S C Derrick; S L Morris
Journal:  Clin Vaccine Immunol       Date:  2013-12-26

2.  Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate.

Authors:  Hillarie Plessner Windish; Malcolm S Duthie; Ayesha Misquith; Greg Ireton; Elyse Lucas; John D Laurance; Remy H Bailor; Rhea N Coler; Steven G Reed
Journal:  Vaccine       Date:  2011-08-02       Impact factor: 3.641

3.  Tuberculosis vaccines: current progress.

Authors:  Ian M Orme
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Assessment of five antigens from Mycobacterium tuberculosis for serodiagnosis of tuberculosis.

Authors:  Xiu-Yun He; Jing Li; Juan Hao; Hong-Bing Chen; Ya-Zhen Zhao; Xiang-Yu Huang; Ke He; Li Xiao; Li-Ping Ye; Yi-Mei Qu; Lin-Hu Ge
Journal:  Clin Vaccine Immunol       Date:  2011-02-02

5.  Multivalent TB vaccines targeting the esx gene family generate potent and broad cell-mediated immune responses superior to BCG.

Authors:  Daniel O Villarreal; Jewell Walters; Dominick J Laddy; Jian Yan; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.

Authors:  Kristopher Kolibab; Amy Yang; Steven C Derrick; Thomas A Waldmann; Liyanage P Perera; Sheldon L Morris
Journal:  Clin Vaccine Immunol       Date:  2010-03-31

7.  Characterization of the protective T-cell response generated in CD4-deficient mice by a live attenuated Mycobacterium tuberculosis vaccine.

Authors:  Steven C Derrick; Teresa H Evering; Vasan K Sambandamurthy; Kripa V Jalapathy; Tsungda Hsu; Bing Chen; Mei Chen; Robert G Russell; Ana Paula Junqueira-Kipnis; Ian M Orme; Steven A Porcelli; William R Jacobs; Sheldon L Morris
Journal:  Immunology       Date:  2006-10-31       Impact factor: 7.397

8.  Enhanced protective efficacy against Mycobacterium tuberculosis afforded by BCG prime-DNA boost regimen in an early challenge mouse model is associated with increased splenic interleukin-2-producing CD4 T-cell frequency post-vaccination.

Authors:  Han Kang; Qin Yuan; Hui Ma; Zhi-Dong Hu; De-Ping Han; Kang Wu; Douglas B Lowrie; Xiao-Yong Fan
Journal:  Immunology       Date:  2014-12       Impact factor: 7.397

9.  A multi-valent vaccinia virus-based tuberculosis vaccine molecularly adjuvanted with interleukin-15 induces robust immune responses in mice.

Authors:  Pin-Yu Perera; Steven C Derrick; Kristopher Kolibab; Fumiki Momoi; Masafumi Yamamoto; Sheldon L Morris; Thomas A Waldmann; Liyanage P Perera
Journal:  Vaccine       Date:  2009-02-06       Impact factor: 3.641

10.  Comparison of BCG prime-DNA booster and rBCG regimens for protection against tuberculosis.

Authors:  Kun Tan; Jinping Liang; Xindong Teng; Xiaochun Wang; Jingyan Zhang; Xuefeng Yuan; Xionglin Fan
Journal:  Hum Vaccin Immunother       Date:  2013-11-05       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.